Company research
Kairos Pharma, LTD.
CIK 1962011Updated Sep 24, 2026
SecurityKAPA · NYSE_AMERICAN · equity
KAPA price & chart
Loading TradingView…
AMEX:KAPA on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
DEFA14A filing
ARS filing
DEF 14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 6,540,000Source | 5,768,000Source | 965,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 62,000Source | 222,000Source | 382,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,491,000Source | — | — |
| Assets, CurrentUSD | 5,387,000Source | 4,169,000Source | 101,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 51,000Source | 38,000Source | 8,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | — | 992,000Source | 3,043,000Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 21,000Source | 14,000Source | 11,000Source |
| Additional Paid in CapitalUSD | 20,582,000Source | 13,577,000Source | 4,123,000Source |
| Retained Earnings (Accumulated Deficit)USD | -14,262,000Source | -8,815,000Source | -6,212,000Source |
| Stockholders' Equity Attributable to ParentUSD | 6,341,000Source | 4,776,000Source | -2,078,000Source |
| Liabilities and EquityUSD | 6,540,000Source | 5,768,000Source | 965,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 199,000Source | 992,000Source | 2,405,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -3,441,000Source | -3,955,000Source | 81,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,660,000Source | 5,134,000Source | -425,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 3,219,000Source | 1,179,000Source | -344,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,491,000Source | 1,272,000Source | 93,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 3,000Source | — |
| Additional Financial Items | |||
| Amortization of Intangible AssetsUSD | 160,000Source | 160,000Source | 160,000Source |
| General and Administrative ExpenseUSD | 3,437,000Source | 1,929,000Source | 1,632,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | 35,000Source | 42,000Source |
| Net Income (Loss) Attributable to ParentUSD | -5,447,000Source | -2,603,000Source | -1,812,000Source |
| Nonoperating Income (Expense)USD | 125,000Source | -260,000Source | -98,000Source |
| Operating ExpensesUSD | 5,572,000Source | 2,343,000Source | 1,714,000Source |
| Payments of Financing CostsUSD | — | 390,000Source | 425,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -5,572,000Source | -2,343,000Source | -1,714,000Source |
| Net Income (Loss) Attributable to ParentUSD | -5,447,000Source | -2,603,000Source | -1,812,000Source |
| Earnings Per Share, BasicUSD per share | -0.3Source | -0.23Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | -0.3Source | -0.23Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 18,427,787Source | 11,356,451Source | 10,382,515Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,427,787Source | 11,356,451Source | 10,382,515Source |
| Interest Expense (non-operating)USD | — | 35,000Source | 42,000Source |
| Additional Financial Items | |||
| Amortization of Intangible AssetsUSD | 160,000Source | 160,000Source | 160,000Source |
| General and Administrative ExpenseUSD | 3,437,000Source | 1,929,000Source | 1,632,000Source |
| Investment Income, NetUSD | 125,000Source | — | — |
| Nonoperating Income (Expense)USD | 125,000Source | -260,000Source | -98,000Source |
| Operating ExpensesUSD | 5,572,000Source | 2,343,000Source | 1,714,000Source |
| Research and Development ExpenseUSD | 2,135,000Source | 414,000Source | 82,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-08-21
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Announces 1-for-7 Reverse Stock Split LOS ANGELES - August 21, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:0…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-22
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer Combination Targets a $570M - $1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC LOS ANGELES - July 22, 2026 - Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaborati…
Read attachment ↗ex99-1.htm · 8-K · 2026-07-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients - Targeting a $10 Billion Drug Resistance Market Zero Grade 3+ Toxicities associated with ENV-105 in 13 Patients; ENV-105 (Carotuximab) Demonstrates Clean Safety Profile in Combination with Osimertinib (AstraZeneca’s Tagrisso®) - Advancing Kairos’s Mission to Resensitize the Largest Unmet Need Population in Lung Cancer LOS ANGEL…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-04
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders LOS ANGELES, June 4, 2026 - (Business Wire) - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: To our valued Kairos Pharma Sharehol…
Read attachment ↗